Literature DB >> 2822079

Radioimmunoscintigraphy of ocular melanoma with 99mTc labelled cutaneous melanoma antibody fragments.

J Bomanji1, J L Hungerford, M Granowska, K E Britton.   

Abstract

The possibility of using radiolabelled monoclonal antibody fragments to image uveal melanomas has been assessed in a pilot study. 99mTc labelled F(ab')2 fragments of MoAb 225.28S raised against cutaneous melanomas were used. Initially 10 patients were imaged. In five patients the clinical findings were typical of uveal melanoma. Immunoscintigraphy was positive in all five cases. In a further five patients there was doubt about the diagnosis. One was though to have a choroidal haemangioma but failed to respond to treatment and immunoscintigraphy was positive, suggesting a diagnosis of melanoma. Two patients were assigned a diagnosis of choroidal haemangioma, one of melanocytoma or possible retinal pigment epithelium carcinoma, and one of metastasis. Immunoscintigraphy was negative in all these four cases. In combination with established diagnostic tests immunoscintigraphy may have a part to play in differentiating uveal melanoma from other similar tumours.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2822079      PMCID: PMC1041268          DOI: 10.1136/bjo.71.9.651

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  22 in total

1.  The use of the 32P test in the management of malignant melanoma of the choroid: a five-year follow-up study.

Authors:  W S Hagler; W H Jarrett; J H Killian
Journal:  Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol       Date:  1977 Jan-Feb

Review 2.  The 32P test and other methods in the diagnosis of intraocular tumors. (Thesis).

Authors:  R A Van Dijk
Journal:  Doc Ophthalmol       Date:  1978-10-16       Impact factor: 2.379

3.  False-positive 32P uptake tests.

Authors:  Z N Zakov; T R Smith; D M Albert
Journal:  Arch Ophthalmol       Date:  1978-12

4.  Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 653.40S to human melanoma cells.

Authors:  P G Natali; K Imai; B S Wilson; A Bigotti; R Cavaliere; M A Pellegrino; S Ferrone
Journal:  J Natl Cancer Inst       Date:  1981-09       Impact factor: 13.506

5.  Osseous choristoma of the choroid simulating a choroidal melanoma. Association with a positive 32P test.

Authors:  A T Williams; R L Font; H J Van Dyk; F T Riekhof
Journal:  Arch Ophthalmol       Date:  1978-10

6.  False-positive results with the radioactive phosphorus test.

Authors:  H F Shammas; T C Burton; T A Weingeist
Journal:  Arch Ophthalmol       Date:  1977-12

7.  Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells.

Authors:  T F Bumol; R A Reisfeld
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

8.  Reappraisal of Callender's spindle a type of malignant melanoma of choroid and ciliary body.

Authors:  I W McLean; L E Zimmerman; R M Evans
Journal:  Am J Ophthalmol       Date:  1978-10       Impact factor: 5.258

9.  Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies.

Authors:  B S Wilson; K Imai; P G Natali; S Ferrone
Journal:  Int J Cancer       Date:  1981-09-15       Impact factor: 7.396

10.  A new melanoma seeker for possible clinical use: selective accumulation of radiolabelled thiouracil.

Authors:  L Dencker; B Larsson; K Olander; S Ullberg
Journal:  Br J Cancer       Date:  1982-01       Impact factor: 7.640

View more
  10 in total

1.  Ocular melanoma.

Authors:  A B Tullo; C L Dodd; J L Noble; S Owens; H Rao
Journal:  Br J Ophthalmol       Date:  1989-09       Impact factor: 4.638

2.  Immunoscintigraphy for ocular melanoma: a reliable diagnostic technique?

Authors:  K U Loeffler; P Bräutigam; J C Simon; S R Althauser; C Wuttig; H Witschel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-02       Impact factor: 3.117

Review 3.  The present and future of radiolabelled antibodies in oncology.

Authors:  K E Britton; M Granowska
Journal:  Ann Nucl Med       Date:  1993-08       Impact factor: 2.668

4.  Radioimmunoscintigraphy and immunohistochemistry with melanoma-associated monoclonal antibodies in choroidal melanoma: a comparison of the clinical and immunohistochemical results.

Authors:  D F Schaling; J P van der Pol; M J Jager; M J van Kroonenburgh; J A Oosterhuis; D J Ruiter
Journal:  Br J Ophthalmol       Date:  1990-09       Impact factor: 4.638

5.  Radioimmunoscintigraphy with melanoma-associated monoclonal antibody fragments in choroidal melanoma.

Authors:  D F Schaling; M J van Kroonenburgh; R A Borsje; J A Camps; H M Kakebeeke-Kemme; J A Oosterhuis; E K Pauwels
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

6.  European multicentre study on melanoma immunoscintigraphy by means of 99mTc-labelled monoclonal antibody fragments. The European Multicentre Study Group.

Authors:  A G Siccardi; G L Buraggi; P G Natali; G A Scassellati; G Viale; S Ferrone
Journal:  Eur J Nucl Med       Date:  1990

7.  Immunoimaging of choroidal melanoma: assessment of its diagnostic accuracy and limitations in 101 cases.

Authors:  J Scheidler; G Leinsinger; C M Kirsch; O F Scheiffarth; F H Stefani; K G Riedel
Journal:  Br J Ophthalmol       Date:  1992-08       Impact factor: 4.638

8.  123I metaiodobenzylguanidine (MIBG) scintigraphy of retinoblastoma: preliminary experience.

Authors:  J Bomanji; J L Hungerford; J E Kingston; D A Levison; K E Britton
Journal:  Br J Ophthalmol       Date:  1989-02       Impact factor: 4.638

9.  Uptake of 99mTc labelled (Fab')2 fragments of monoclonal antibody 225.28S by a benign ocular naevus.

Authors:  J Bomanji; J L Hungerford; M Granowska; K E Britton
Journal:  Eur J Nucl Med       Date:  1988

10.  Immunoscintigraphy with three step monoclonal pretargeting technique in diagnosis of uveal melanoma: preliminary results.

Authors:  G Modorati; R Brancato; G Paganelli; P Magnani; R Pavoni; F Fazio
Journal:  Br J Ophthalmol       Date:  1994-01       Impact factor: 4.638

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.